This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Sedating antihistamines like cyproheptadine may have additive effects with other CNS depressants like such as alcohol, hypnotics, sedatives, tranquilizers, and anxiolytics. Monoamine oxidase inhibitors (MAOIs) may prolong and intensify the anticholinergic effects of antihistamines like cyproheptadine. However, cyproheptadine is safe to use in the treatment of serotonin syndrome occurring with MAOIs. Cyproheptadine, due to its serotonin 5-HT2A receptor antagonism, may be useful as a hallucinogen antidote against serotonergic psychedelics or as a so-called "trip killer". The drug has been clinically studied in combination with the serotonergic psychedelic dimethyltryptamine (DMT). In an early study, cyproheptadine partially blocked the hallucinogenic effects of DMT in 2 of 3 subjects. In a follow-up study, pretreatment with cyproheptadine in 5 subjects failed to reduce the psychoactive effects of DMT and instead was found to actually intensify its effects in some cases, although the duration of DMT seemed to be shortened. Subsequently, Rick Strassman and colleagues studied cyproheptadine in combination with DMT in 8 subjects and found that the hallucinogenic effects of DMT were not magnified but were reduced. However, owing to the pronounced sedative effects of cyproheptadine, it was difficult to tell how much of cyproheptadine's effect was due to antagonism of DMT versus simple general tranquilization. Overall, the findings have been described as inconclusive and higher doses of cyproheptadine being precluded by the drug's sedative effects.
=== Availability === Suvorexant has been marketed in the United States, Canada, Australia, Russia, and Japan. Although previously available, suvorexant appears to have been discontinued in Canada. It does not appear to be available in the United Kingdom or other European countries besides Russia.
=== Interstitial cystitis === Interstitial cystitis (IC) a type of painful bladder syndrome is a chronic disease of the bladder that causes feelings of pressure and pain in the bladder among other symptoms which can range from mild to severe. Urinary frequency and urgency are the most common symptoms associated with the disease. The exact causes of IC/BPS are unknown, but there is evidence of an association between increased permeability of the urothelium and IC. Since the purpose of the urothelium is to act as a highly resistant barrier, the loss of this function has serious clinical implications. Many patients with IC have exhibited a loss of umbrella cells.
With the help of Charles Stearn, an expert on vacuum pumps, in 1878, Swan developed a method of processing that avoided the early bulb blackening. This received a British Patent in 1880. On 18 December 1878, a lamp using a slender carbon rod was demonstrated at a meeting of the Newcastle Chemical Society though it only worked for a few minutes. Swan repeated the demonstration at another meeting on 17 January 1879 where it worked successfully. It was shown to 700 who attended a meeting of the Literary and Philosophical Society of Newcastle upon Tyne on 3 February 1879. The society's building was the first public building to be lit by electricity. The lamps Swan demonstrated used a carbon rod from an arc lamp rather than a slender filament. Thus they had low resistance and required very large conductors to supply the necessary current, so they were not commercially practical, although they furnished a demonstration of the possibilities of incandescent lighting with relatively high vacuum, a carbon conductor, and platinum lead-in wires. This bulb lasted about 40 hours. Swan then turned his attention to producing a better carbon filament and the means of attaching its ends. He devised a method of treating cotton to produce 'parchmentised thread' in the early 1880s and obtained British Patent 4933 that same year. From this year he began installing light bulbs in homes and landmarks in England. His house, Underhill, Low Fell, Gateshead, was the first in the world to be lit by a lightbulb. In the early 1880s he had started his company.
Sources: en.wikipedia.org
== Drift gas == The drift gas composition is an important parameter for the IMS instrument design and resolution. Often, different drift gas compositions can allow for the separation of otherwise overlapping peaks. Elevated gas temperature assists in removing ion clusters that may distort experimental measurements.
In common with many other developed countries, Canada is experiencing an increase in healthcare expenditures due to a demographic shift toward an older population, with more retirees and fewer people of working age. In 2021, the average age in Canada was 41.9 years. Life expectancy is 81.1 years. A 2016 report by the chief public health officer found that 88 percent of Canadians, one of the highest proportions of the population among G7 countries, indicated that they "had good or very good health". Eighty percent of Canadian adults self-report having at least one major risk factor for chronic disease: smoking, physical inactivity, unhealthy eating or excessive alcohol use. Canada has one of the highest rates of adult obesity among OECD countries, contributing to approximately 2.7 million cases of diabetes. Four chronic diseases—cancer (leading cause of death), cardiovascular diseases, respiratory diseases, and diabetes—account for 65 percent of deaths in Canada. There are approximately 8 million people aged 15 and older with one or more disabilities in Canada. In 2024, the Canadian Institute for Health Information estimated that healthcare spending reached $372 billion, or 12.4 percent of Canada's GDP for that year. In 2022, Canada's per-capita spending on health expenditures ranked 12th among health-care systems in the OECD. The Commonwealth Fund's 2021 report comparing the healthcare systems of the 11 most developed countries ranked Canada second-to-last.
These physical agents are mostly used in surgical settings as well as after surgery treatments. These sponges absorb blood, allow for coagulation to occur faster, and give off chemical responses that decrease the time it takes for the hemostasis pathway to start.
Sources: en.wikipedia.org
=== Machine Learning Force Fields === Machine Learning Force Fields (MLFFs) represent one approach to modeling interatomic interactions in molecular dynamics simulations. MLFFs can achieve accuracy close to that of ab initio methods. Once trained, MLFFs are much faster than direct quantum mechanical calculations. MLFFs address the limitations of traditional force fields by learning complex potential energy surfaces directly from high-level quantum mechanical data. Several software packages now support MLFFs, including VASP and open-source libraries like DeePMD-kit and SchNetPack.
Wastewater treatment plants (WWTPs) are designed to remove contaminants from domestic and industrial wastewater before it is released into the environment. However, some WWTPs, particularly older or under-resourced ones are not equipped to effectively remove all CEC, such as advanced pharmaceuticals, personal care product ingredients, and certain types of industrial chemicals. These substances can pass through the treatment process and enter aquatic ecosystems, which creates a challenge for water treatment technology and emphasizes the need for ongoing research and infrastructure improvement to address the removal of CEC from wastewater. Advances like tertiary treatment stages, which incorporate advanced filtration and chemical removal techniques, are being tested to address the presence of CEC in waste, though widespread implementation is yet to be seen due to novelty, cost, and logistical challenges.
==== Dosage ==== Colistin sulfate and colistimethate sodium may both be given intravenously, but the dosing is complicated. The different labeling of the parenteral products of colistin methanesulfonate in different parts of the world was noted by Li et al. Colistimethate sodium manufactured by Xellia (Colomycin injection) is prescribed in international units, whereas colistimethate sodium manufactured by Parkdale Pharmaceuticals (Coly-Mycin M Parenteral) is prescribed in milligrams of colistin base:
LL-37 has also been found to be a common auto-antigen in psoriasis; T-cells specific to LL-37 were found in the blood and skin in two thirds of patients with moderate to severe psoriasis. LL-37 binds to the peptide Ab, which is associated with Alzheimer's disease. An imbalance between LL-37 and Ab may be a factor affecting AD-associated fibrils and plaques. Chronic, oral Porphyromonas gingivalis, and herpesvirus (HSV-1) infections may contribute to the progression of Alzheimer's dementia.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.